BNXTF Stock Chart & Stats
$0.44
$0.02(7.93%)
At close: 4:00 PM EST
$0.44
$0.02(7.93%)
Day’s Range― - ―
52-Week Range$0.14 - $0.80
Previous CloseN/A
Volume333.00
Average Volume (3M)3.75K
Market Cap
$27.71M
Enterprise Value$67.66
Total Cash (Recent Filing)$12.07K
Total Debt (Recent Filing)$6.30M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding129,994,550
10 Day Avg. Volume3,336
30 Day Avg. Volume3,755
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)-8.07
Price to Sales (P/S)0.00
P/FCF Ratio-14.55
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform Delivery & Licensing PotentialBioNxt’s platform approach—reformulating existing APIs into patient-friendly dosage forms—is a durable business model that can reduce clinical and development risk versus new molecular entities. It supports licensing and partnership revenue streams and leverages established drugs for commercial opportunities over time.
Lean Operating StructureA small, focused team reduces fixed overhead and can extend runway relative to larger R&D organizations. For an early-stage delivery-platform company this lean structure supports nimble program prioritization and efficient use of cash while seeking partner deals or milestone payments.
Improving Loss And Burn Trend Versus Prior YearsReported improvements in net loss and cash burn versus 2021–2022 indicate operational stabilization. While still unprofitable, this trend suggests management has taken cost or program actions that could reduce future financing needs if sustained, improving the odds of achieving near-term milestones or deals.
Bears Say
No Meaningful Revenue BaseRevenue collapsed to effectively zero, demonstrating absence of commercialization or recurring licensing income. Without a revenue base the company cannot self-fund operations, increasing execution risk and making long-term product development and partnership negotiations more difficult.
Balance-sheet Stress And Negative EquityPersistent negative equity alongside meaningful debt constrains financial flexibility and signals reliance on external financing. This structural weakness elevates dilution and recapitalization risk, limits ability to invest in growth or pursue partnerships requiring cash commitments, and raises creditor sensitivity.
Sustained Cash Burn And Negative Free Cash FlowMaterial negative operating and free cash flow indicates the company cannot internally fund its development plan. Continued burn requires new financing or partnerships, which may be dilutive or contingent, and constrains the firm’s ability to execute on longer-term R&D or commercialization initiatives.
BioNxt Solutions News
BNXTF FAQ
What was BioNxt Solutions’s price range in the past 12 months?
BioNxt Solutions lowest stock price was $0.14 and its highest was $0.80 in the past 12 months.
What is BioNxt Solutions’s market cap?
BioNxt Solutions’s market cap is $27.71M.
When is BioNxt Solutions’s upcoming earnings report date?
BioNxt Solutions’s upcoming earnings report date is Aug 31, 2026 which is in 38 days.
How were BioNxt Solutions’s earnings last quarter?
Currently, no data Available
Is BioNxt Solutions overvalued?
According to Wall Street analysts BioNxt Solutions’s price is currently Overvalued.
Does BioNxt Solutions pay dividends?
BioNxt Solutions does not currently pay dividends.
What is BioNxt Solutions’s EPS estimate?
BioNxt Solutions’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioNxt Solutions have?
BioNxt Solutions has 129,994,550 shares outstanding.
What happened to BioNxt Solutions’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioNxt Solutions?
Currently, no hedge funds are holding shares in BNXTF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioNxt Solutions
Headquartered in Vancouver, Canada, BioNxt Solutions Inc., established in 2017, operates as a bioscience company across Germany, Switzerland, Austria, Israel, and its home country. The firm focuses on developing innovative drug delivery systems, including transdermal patches and oral dissolvable films, specifically for neurological medications. It also advances psychedelic medicine applications to treat various mental health conditions such as depression, anxiety, addiction, and trauma-related stress disorder. Furthermore, BioNxt is engaged in creating point-of-care diagnostics, comprising rapid tests and biosensor screening tools, aimed at early disease detection, improved treatment efficacy, and enhanced disease management. This diagnostic portfolio features a COVID-19 PCR kit, alongside oral biosensors for peri-implantitis, H1N1 (swine flu), and H5N1 (avian flu). Complementing its development efforts, the company provides analytical testing and consulting services, and is involved in pathogen and oral health diagnostics, thin film drug formulation, and the production and formulation of psychedelic pharmaceuticals. The company adopted its current name in November 2022, having previously been known as XPhyto Therapeutics Corp.
Technical Analysis
Willow Biosciences Inc
―
Quantum Biopharma
―
MediPharm Labs
―
Avicanna
―
InnoCan Pharma
―